



LASD

Lasco Distributors Limited (LASD);

Opening price— \$3.53;

Price to book— 1.16 times;

P/E- 9.69 times

Week to Date:

Month to Date:

Quarter to Date: 0.80%

Year to Date:

Our weekly pick features a stock currently held in the **Mayberry Managed Equity** Portfolio (MMEP). For more information on the MMEP, please contact your investment advisor today.

Featured Stock

LASCO Distributors Limited is a leading distribution company in Jamaica. Established over 30 years ago, the company quickly expanded its market presence by offering quality products at competitive prices. LASCO distributes both local and international brands, as well as its own private labels. The company operates through two main divisions: the Consumer Division and the Pharmaceutical Division.

LASCO Distributors Limited (LASD) reported a 1% decline in revenue for the first quarter ended June 30, 2025, with earnings of \$7.27 billion compared to \$7.33 billion in the corresponding period of the previous year.

Cost of sales amounted to \$6.01 billion, slightly above the \$6.00 billion recorded in 2024. As a result, gross profit fell by 5% to \$1.26 billion, down from \$1.32 billion in the prior year.

Operating expenses for the quarter totaled \$981.98 million, reflecting a 4% increase over the \$941.25 million reported in 2024. Consequently, operating profit declined by 18% to \$362.16 million, compared to \$441.30 million in the prior year.

Finance costs rose sharply to \$7.80 million, representing a 2,619% increase relative to \$287,000 in the corresponding quarter of 2024. Profit before taxation stood at \$354.36 million, a 20% decrease from the \$441.01 million recorded last year.

The taxation charge decreased by 39% to \$50.41 million, compared to \$82.10 million in 2024. Net profit for the period amounted to \$303.95 million, representing a 15% decline from \$358.91 million in the prior year. Total comprehensive income also decreased by 19%, closing the guarter at \$295.17 million compared to \$363.28 million in 2024.

LASD's management team notes, "The company is completely focused on improving execution and operational efficiencies, leveraging the recent investments in technology and training to deliver growth in its core categories, while accelerating expansion is other businesses. The Pharmaceutical Division's ongoing transformation are expected to further diversify the company's portfolio, and the Export business is expected to continue to deliver accretive growth."

LASD (as at Monday September 08th, 2025) was trading at 1.16 times its book value with a P/E of 9.69 times.



